Factor VIII gene therapy - Genetic Therapy

Drug Profile

Factor VIII gene therapy - Genetic Therapy

Latest Information Update: 28 Aug 2007

Price : $50

At a glance

  • Originator Genetic Therapy
  • Developer Genetic Therapy; Nonindustrial source
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Haemophilia

Most Recent Events

  • 04 Dec 2003 No development reported - Preclinical for Haemophilia in USA (IV)
  • 20 Jun 2001 Preclinical development for Haemophilia in USA (IV)
  • 30 Jul 1998 No-Development-Reported for Haemophilia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top